We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

128 hedge funds and large institutions have $640M invested in KalVista Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

22,781% more call options, than puts

Call options by funds: $15.8M | Put options by funds: $69K

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

37% more capital invested

Capital invested by funds: $467M → $640M (+$173M)

25% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 36

8% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 24

1.22% less ownership

Funds ownership: 111.68% → 110.46% (-1.2%)

2% less funds holding

Funds holding: 130 → 128 (-2)

Holders
128
Holders Change
-2
Holders Change %
-1.54%
% of All Funds
1.72%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
22
Increased
45
Reduced
36
Closed
24
Calls
$15.8M
Puts
$69K
Net Calls
+$15.7M
Net Calls Change
+$17.4M

Top Buyers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
+$11.1M
2
PHP
Parkman Healthcare Partners
Connecticut
+$7.69M
3
SSA
Schonfeld Strategic Advisors
New York
+$5.94M
4
VA
VR Adviser
New York
+$4.64M
5
JP Morgan Chase
JP Morgan Chase
New York
+$3.89M

Top Sellers

Rank Fund Capital Flow
1
BCM
Boxer Capital Management
California
-$13.5M
2
GPP
Great Point Partners
Connecticut
-$7.89M
3
SC
Stempoint Capital
New York
-$6.18M
4
SVCM
Saturn V Capital Management
Texas
-$3.08M
5
State Street
State Street
Massachusetts
-$3.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$4.47M +$218K +21,392 +6%
SC
27
Stempoint Capital
New York
$4.46M -$6.18M -605,966 -61%
JFG
28
Jefferies Financial Group
New York
$4.33M – – –
Goldman Sachs
29
Goldman Sachs
New York
$3.92M +$125K +12,263 +4%
Bank of America
30
Bank of America
North Carolina
$3.56M +$2.02M +198,197 +180%
RA
31
Rosalind Advisors
Ontario, Canada
$3.51M – – –
Adage Capital Partners
32
Adage Capital Partners
Massachusetts
$3.19M -$245K -24,000 -8%
SVCM
33
Saturn V Capital Management
Texas
$2.94M -$3.08M -301,429 -54%
Walleye Capital
34
Walleye Capital
New York
$2.88M -$190K -18,582 -7%
Morgan Stanley
35
Morgan Stanley
New York
$2.58M -$671K -65,726 -23%
Millennium Management
36
Millennium Management
New York
$2.29M +$2.02M +198,205 New
UOC
37
UBS O'Connor
Illinois
$1.96M -$30.6K -3,001 -2%
CPA
38
Capital Performance Advisors
California
$1.8M +$39.2K +3,845 New
NFGH
39
Nan Fung Group Holdings
Hong Kong
$1.78M – – –
Citigroup
40
Citigroup
New York
$1.71M -$1.83M -179,069 -55%
DP
41
Diadema Partners
New Jersey
$1.56M +$1.38M +135,509 New
Wellington Management Group
42
Wellington Management Group
Massachusetts
$1.46M +$34.8K +3,405 +3%
Charles Schwab
43
Charles Schwab
California
$1.31M +$130K +12,776 +13%
HWAM
44
Hennion & Walsh Asset Management
New Jersey
$1.28M +$370K +36,279 +48%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$1.19M +$50.9K +4,983 +5%
Fidelity Investments
46
Fidelity Investments
Massachusetts
$957K +$9.09K +891 +1%
Marshall Wace
47
Marshall Wace
United Kingdom
$934K -$378K -37,013 -31%
PAM
48
Panagora Asset Management
Massachusetts
$830K – – –
BC
49
Birchview Capital
Vermont
$773K +$20 +2 +0%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$704K -$48K -4,705 -7%
1
2
3 4 5

KALV Hedge Fund Activity: Q1 2025 in Review

128 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2025, worth a combined $640M — up 37% from $467M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of KALV and 22 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 45 added.

The largest buyer was Silverarc Capital Management, adding an estimated $11.1M. The largest seller was Boxer Capital Management, exiting entirely with an estimated $13.5M sold.

  • 128 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2025, down from 130 in Q4 2024.
  • Funds reported $640M of KalVista Pharmaceuticals stock for Q1 2025, up 37% quarter-over-quarter.
  • 22 funds opened new KalVista Pharmaceuticals positions in Q1 2025 and 24 closed out, a net change of -2 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2025 was Silverarc Capital Management, an estimated $11.1M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2025 was Boxer Capital Management, an estimated $13.5M sold.

Based on aggregated 13F filings for Q1 2025.